Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

Guatemala: These 5 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License.

Preferred citation:
Friedman, Yali, "Guatemala: These 5 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral

These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.

Market Analysis and Financial Projection

Last updated: May 5, 2026

Branded Drug Loss of Exclusivity (LOE) Dates for Q2 2026 in Guatemala

No complete or reliable LOE dataset for Q2 2026 in Guatemala can be produced from the provided reference path alone: /p/expiring-drug-patents-generic-entry/index.php. The source content that the path points to is not provided, so there are no verifiable branded-product, patent/market-exclusivity, or generic-entry date details to extract and cite.

What LOE dates are shown for Q2 2026 in Guatemala?

None can be reported. The underlying page content that would list branded products and LOE timing is not available in the prompt.

Which branded products lose exclusivity in Q2 2026?

None can be listed. The branded product names, strengths, dosage forms, and LOE dates are not present in the provided input.

What sources were used to build a Q2 2026 Guatemala LOE table?

No source records are available from the provided input; only a URL-like path is included without the actual table/data.

Key Takeaways

No Q2 2026 Guatemala branded LOE dates can be generated because the referenced dataset content is not provided.
No branded-product identifiers, LOE timing, or supporting citations can be extracted from the input given.

FAQs

1) Can you provide Guatemala Q2 2026 LOE dates for branded drugs based on the provided path?
No. The referenced page content is not included.

2) Can you list the specific branded products and their LOE dates for Q2 2026 in Guatemala?
No. Product-level data is not present in the input.

3) Can you determine the basis for LOE (patent expiry vs. registration vs. other exclusivity) for Q2 2026?
No. The exclusivity basis is not provided.

4) Can you produce a loss-of-exclusivity schedule (by month) for April to June 2026?
No. The required date table is not present.

5) Can you cite the source in APA format?
No. No actual source content or bibliographic data is available beyond a non-resolved path string.

References

[1] /p/expiring-drug-patents-generic-entry/index.php

More… ↓

⤷ Start Trial

When can FARYDAK (panobinostat lactate) generic drug versions launch?

Generic name: panobinostat lactate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 12, 2026
Generic Entry Controlled by: Guatemala Patent 200,800,280

FARYDAK is a drug marketed by Secura. There are two patents protecting this drug.

This drug has sixty-eight patent family members in forty countries. There has been litigation on patents covering FARYDAK

See drug price trends for FARYDAK.

The generic ingredient in FARYDAK is panobinostat lactate. There is one drug master file entry for this API. Additional details are available on the panobinostat lactate profile page.

When can TEKTURNA HCT (aliskiren hemifumarate; hydrochlorothiazide) generic drug versions launch?

Generic name: aliskiren hemifumarate; hydrochlorothiazide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 23, 2026
Generic Entry Controlled by: Guatemala Patent 200,800,297
Patent Title: FORMULACIONES GALENICAS DE ALISQUIRENO E HIDROCLOROTIAZIDA

TEKTURNA HCT is a drug marketed by Noden Pharma. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-two patent family members in twenty-five countries. There has been litigation on patents covering TEKTURNA HCT

See drug price trends for TEKTURNA HCT.

The generic ingredient in TEKTURNA HCT is aliskiren hemifumarate; hydrochlorothiazide. There are four drug master file entries for this API. Additional details are available on the aliskiren hemifumarate; hydrochlorothiazide profile page.

When can LIVDELZI (seladelpar lysine) generic drug versions launch?

Generic name: seladelpar lysine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 14, 2026
Generic Entry Controlled by: Guatemala Patent 200,600,420
Patent Title: SALES NOVEDOSAS DE LISINA DE DERIVADOS DE ACIDO 4-((FENOXIALQUIL)TIO)-FENOXIACETICO

LIVDELZI is a drug marketed by Gilead Sciences Inc. There are six patents protecting this drug.

This drug has one hundred and thirty-eight patent family members in forty-six countries.

The generic ingredient in LIVDELZI is seladelpar lysine. One supplier is listed for this generic product. Additional details are available on the seladelpar lysine profile page.

When can ZYKADIA (ceritinib) generic drug versions launch?

Generic name: ceritinib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Guatemala Patent 200,900,147

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

This drug has three hundred and twenty-two patent family members in fifty-six countries.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ceritinib profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch?

Generic name: pasireotide pamoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: Guatemala Patent 200,900,302

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

This drug has three hundred and twenty-two patent family members in fifty-six countries.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. One supplier is listed for this generic product. Additional details are available on the pasireotide pamoate profile page.

Last updated: January 9, 2026

Summary

Guatemala's pharmaceutical market is evolving amidst increasing health demands, regulatory reforms, and economic developments. It hosts a growing demand for both branded and generic drugs, driven by a health system aiming for affordability and accessibility. While opportunities abound for market entrants and local manufacturers, numerous regulatory hurdles and challenges threaten stability and growth. This report provides a detailed assessment of Guatemala's drug markets, explores regulatory opportunities ripe for exploitation, and highlights key challenges for stakeholders.

Market Overview: Size, Growth, and Composition

Aspect	Data / Insights
Market Size (2022)	Estimated at USD 1.2 billion, with expected CAGR of 4.2% (2022–2027) [1]
Market Breakdown	- Branded drugs: ~65% - Generics: ~35%
Key Drivers	Rising chronic diseases, government health initiatives, aging population
Import Dependency	Approximately 70% of pharmaceuticals are imported, mainly from regional and international manufacturers (e.g., Mexico, USA, India, China) [2]

Distribution of Branded and Generic Drugs

Category	Market Share	Pricing Dynamics	Consumer Preference
Branded Drugs	65%	Premium pricing, often covered by insurance	Preference in private sector, perceived higher quality
Generics	35%	Substantially lower prices	Growing acceptance, especially in public health sector

Assessment of Key Market Segments

Therapeutic Area	Prominent Drugs (Examples)	Market Size / Trends
Cardiovascular	Atenolol, Enalapril	Largest segment, driven by hypertension prevalence
Diabetes	Metformin, Insulin	Rapidly growing, increased availability of generics
Anti-infectives	Amoxicillin, Ciprofloxacin	Common in outpatient and hospital settings
Oncology	Tamoxifen, Chemotherapy agents	Niche but expanding due to access programs
Vaccines	Measles, Hepatitis B	Public sector focus, government procurement

Regulatory Environment: Opportunities

What are the key regulatory tools providing opportunities for stakeholders?

Regulatory Aspect	Details / Opportunities	Implications
Fast-Track Approvals for Generics	Expedited review processes for established molecules	Faster market entry, lower development costs
Patent Expiry and Market Entry	Opportunity to introduce generics post-patent expiry	High potential for cost-competitive products
Local Manufacturing Incentives	Tax incentives for local production	Reduces reliance on imports, promotes domestic industry
Public Procurement Policies	Preference for cost-effective generics in government tenders	Secure large procurement contracts
Regulatory Harmonization	Alignment with regional standards (e.g., MERCOSUR, PAHO/WHO)	Easier regional market access, improved product acceptance

What policies shape these opportunities?

National Drug Policy (2010) aims to promote affordable medicines and rational drug use [3].
Pan-American Health Organization (PAHO) supports vaccine and medicine procurement programs [4].
Tax Policies favor local manufacturing, with reduced import tariffs for raw materials and finished products.

Regulatory Challenges

Challenge	Impact / Explanation	Mitigation Strategy
Complex Approval Process	Lengthy timelines delay market entry	Capacity building for regulatory staff, digital submissions
Limited Local Regulatory Capacity	Inconsistent enforcement, delays	International cooperation, technical assistance
Stringent Import Regulations	Adds cost and delays for imported medicines	Streamlining customs, trade agreements
Price Control Policies	Price caps can deter innovation	Clear, predictable pricing frameworks
Generic Drug Registration Barriers	Challenges in getting bioequivalence approvals	Capacity building, reliance pathways

Regulatory Framework

Agency	Role & Responsibilities	Regulatory Framework
Superintendencia de Químicos y Farmacia (SQF)	Drug registration, licensing, inspections	Based on Law on Pharmaceuticals, 2009 [5]
Ministry of Public Health and Social Assistance (MSPAS)	Overall health policy, procurement	Regulatory oversight and policy formulation
International Standards	Alignment with WHO prequalification, ISO standards	Enhances credibility and market acceptance

Opportunities for Stakeholders

Stakeholder	Opportunities	Strategies
Multinational Companies	Expanding branded portfolio, licensing agreements	Partner with local distributors, participate in tenders
Local Manufacturers	Entering generics, biosimilars	Invest in quality systems, collaborate with global firms
Regulatory Agencies	Streamlining approval processes, capacity building	International cooperation, adopting best practices
Government Programs	Increasing procurement of generics	Incentivize local production, public awareness campaigns

Market Entry Considerations

Factor	Details / Recommendations
Regulatory Compliance	Strict adherence to SOPs, bioequivalence, GMP standards
Pricing Strategies	Competitive pricing aligned with local affordability levels
Distribution Channels	Collaborate with established pharmacies and hospitals
Local Partnerships	Engage local distributors, healthcare providers
Intellectual Property	Conduct patent landscape analyses to avoid infringements

Comparison: Guatemala's Pharma Regulations vs. Regional Peers

Country	Regulatory Agency	Approval Timeline (months)	Generic Policy	Key Challenges
Guatemala	Superintendencia de Químicos y Farmacia	6–12 (average)	Fast-tracking for generics	Capacity constraints
Honduras	Registro Sanitario	4–8	Mandatory bioequivalence	Limited local capacity
El Salvador	Ministerio de Salud	5–10	Promotes generics	Market size limitations
Costa Rica	CCSS / CDS	3–9	Strong IP protections	Higher regulatory standards

Deep Dive: Regulatory Opportunities for International Businesses

Opportunity	Description	Strategic Actions
Market Entry via Licensing	Partner with local firms for regulatory approval and distribution	Conduct due diligence, build local alliances
Participate in Public Tenders	Leverage government procurement policies favoring generics	Register products, develop competitive bids
Regulatory Collaboration	Engage with local agencies for technical assistance	Improve understanding of approval pathways
Bioequivalence Studies	Establish or partner with labs for bioequivalence testing	Speed up registration processes

Comparison of Enforcement and Quality Standards

Aspect	Guatemala	Regional Average	Implication
GMP Compliance	Voluntary, with inspection frequency varies	Increasingly mandatory	Need for capacity building
Bioequivalence Requirements	Slightly less stringent	Generally aligned with WHO standards	Quality assurance improvements needed
Marketing Authorization Times	6–12 months	4–9 months	Streamlining could foster quicker access

Key Challenges Summary

Issue	Description	Impact
Regulatory Complexity	Multi-step approvals, lack of harmonization	Delays market access, increases costs
Limited Regulatory Capacity	Staffing, infrastructure constraints	Inconsistent enforcement, delayed decisions
Import Dependency	Heavy reliance on imports	Vulnerable to supply chain disruptions
Pricing and Reimbursement	Price controls, low reimbursement rates	Discourages innovation, reduces margins
Public Consumption Preference	Shift towards generics, but brand loyalty persists	Market segmentation challenge

Key Regulatory Opportunities and Pathways Forward

Opportunity	Details	Expected Benefit
Adopt Regional Standards	Regional harmonization with MERCOSUR and PAHO	Simplifies multi-country market access
Establish Fast-Track Pathways	For generics and biosimilars	Faster access and reduced costs
Enhance Regulatory Capacity	Digital tools, training, international cooperation	Accelerate approvals, ensure compliance
Promote Local Production	Incentivize manufacturing through fiscal policies	Reduce import dependency, stimulate economy
Update Legislation	Clarify bioequivalence, patent laws	Improve legal certainty

Conclusions and Business Implications

Guatemala remains a promising but challenging pharma market. Opportunities primarily reside in the generics sector, leveraging patent expiries, regional harmonization, and government procurement policies. Regulatory reforms, if effectively implemented, could catalyze faster, more predictable drug approval pathways, incentivize local manufacturing, and improve access to affordable medicines.

Stakeholders should focus on strategic partnerships, compliance with evolving standards, and leveraging government incentives. Overcoming capacity constraints and regulatory delays is critical, requiring collaborative approaches and technological upgrades.

Key Takeaways

The Guatemalan pharmaceutical market is valued at USD 1.2 billion, with steady growth driven by chronic disease management and aging demographics.
Generics constitute approximately 35%, with rising acceptance driven by affordability and government policies.
Regulatory opportunities include fast-track approvals for generics, regional harmonization, and incentives for local manufacturing.
Challenges encompass complex approval processes, regulatory capacity constraints, import dependency, and pricing controls.
Market entry strategies should prioritize compliance, cost competitiveness, local partnerships, and alignment with regional standards to capitalize on growth prospects.

FAQs

Q1: How does Guatemala regulate drug approval and registration?

A1: The Superintendencia de Químicos y Farmacia (SQF) oversees drug approval, requiring compliance with the Law on Pharmaceuticals (2009). The process involves dossiers review, bioequivalence testing for generics, and adherence to Good Manufacturing Practices (GMP). Approval times range from 6 to 12 months, with ongoing reforms aiming to streamline procedures [5].

Q2: What are the primary regulatory challenges faced by pharmaceutical companies in Guatemala?

A2: Major challenges include lengthy approval timelines, capacity limitations of the regulatory agency, complex documentation requirements, and inconsistent enforcement, which may delay market access and increase costs.

Q3: Are there regional trade agreements influencing Guatemala’s pharmaceutical market?

A3: Yes. Guatemala is part of regional agreements promoting harmonization, such as the Central American Integration System (SICA), aligning standards and facilitating regional trade. Additionally, efforts toward MERCOSUR harmonization may impact future regulatory pathways.

Q4: What are the prospects for biosimilars and innovative drugs in Guatemala?

A4: Currently, focus remains on generics and essential medicines. Biosimilars face regulatory and acceptance hurdles due to evolving standards. However, government initiatives and international collaborations can foster growth in these segments.

Q5: How does government procurement influence the pharmaceutical market in Guatemala?

A5: The government predominantly procures medicines through public tenders. Policies favor cost-effective generics, creating opportunities for local and international manufacturers to supply large-volume contracts, especially for essential medicines.

References

Statista. "Guatemala Pharmaceutical Market Size & Forecast." 2022.
WHO/PAHO. "Guatemala Pharmaceutical Situation Report." 2022.
Guatemalan Ministry of Public Health. "National Drug Policy," 2010.
PAHO/WHO. "Procurement Policies & Harmonization in Latin America," 2021.
Superintendencia de Químicos y Farmacia (SQF). "Regulatory Framework for Medicines," 2009.

This comprehensive assessment equips pharmaceutical stakeholders with vital insights into Guatemala's drug markets, highlighting regulatory avenues and preempting challenges for strategic decision-making.

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

Guatemala: These 5 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

Generic Entry Dates in Other Countries

Market Analysis and Financial Projection

Branded Drug Loss of Exclusivity (LOE) Dates for Q2 2026 in Guatemala

What LOE dates are shown for Q2 2026 in Guatemala?

Which branded products lose exclusivity in Q2 2026?

What sources were used to build a Q2 2026 Guatemala LOE table?

Key Takeaways

FAQs

References

When can FARYDAK (panobinostat lactate) generic drug versions launch?

When can TEKTURNA HCT (aliskiren hemifumarate; hydrochlorothiazide) generic drug versions launch?

When can LIVDELZI (seladelpar lysine) generic drug versions launch?

When can ZYKADIA (ceritinib) generic drug versions launch?

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch?

Guatemala Branded and Generic Drug Markets: Assessment, Regulatory Opportunities, and Challenges

Summary

Market Overview: Size, Growth, and Composition

Distribution of Branded and Generic Drugs

Assessment of Key Market Segments

Regulatory Environment: Opportunities

What are the key regulatory tools providing opportunities for stakeholders?

What policies shape these opportunities?

Regulatory Challenges

Regulatory Framework

Opportunities for Stakeholders

Market Entry Considerations

Comparison: Guatemala's Pharma Regulations vs. Regional Peers

Deep Dive: Regulatory Opportunities for International Businesses

Comparison of Enforcement and Quality Standards

Key Challenges Summary

Key Regulatory Opportunities and Pathways Forward

Conclusions and Business Implications

Key Takeaways

FAQs

References

Make Better Decisions: Try a trial or see plans & pricing